Arcellx, Inc. (ACLX)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Rami Elghandour | Chairman of the Board, CEO & President | 941.67k | -- | 1979 |
| Ms. Michelle Lim Gilson | Chief Financial Officer | 602.8k | -- | 1993 |
| Dr. Christopher R. Heery M.D. | Chief Medical Officer | 683.4k | -- | 1980 |
| Mr. Narinderjeet Singh M.S. | Chief Technical Officer | -- | -- | 1972 |
| Mr. David Tice Ph.D. | Chief Scientific Officer | -- | -- | 1971 |
| Ms. Myesha Lacy | Chief Investor & Communications Officer | -- | -- | -- |
| Ms. Maryam Abdul-Kareem J.D., M.S. | General Counsel & Chief Legal Officer | -- | -- | -- |
| Ms. Kate Aiken | Chief People Officer | -- | -- | -- |
| Mr. Neeraj P. Teotia | Chief Commercial Officer | 461.95k | -- | 1975 |
| Ms. Aileen Fernandes | Chief Business Officer | -- | -- | -- |
Arcellx, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 130
Description
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Corporate Governance
Recent Events
- Apr 11, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Mar 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 28, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 31, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 29, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing
Upcoming Events
Upcoming Events Information Not Available